Evidence mapPaperPMID 36427170Full record

SynthesisEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2023

Prevalence of visceral leishmaniasis among people with HIV: a systematic review and meta-analysis.

Maria Kantzanou, Maria A Karalexi, Kalliopi Theodoridou, Evangelos Kostares, Georgia Kostare, Thalia Loka, Georgia Vrioni, Athanassios Tsakris

Open access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Assessment of asymptomaticFrontiers in medicine · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Knock, knock, knocking on EuropeCurrent research in parasitology & vector-borne diseases · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Maria KantzanouDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece.
Maria A KaralexiDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece.
Kalliopi TheodoridouDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece.
Evangelos KostaresDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece.
Georgia KostareDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece.
Thalia LokaDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece.
Georgia VrioniDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece.
Athanassios TsakrisDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece. atsakris@med.uoa.gr.ORCID http://orcid.org/0000-0003-0656-4715
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a parasitic infection expressing different clinical phenotypes. Visceral leishmaniasis (VL) is considered an opportunistic infection among people with human immunodeficiency virus (HIV). The objective of this review was to identify published data on the prevalence of Leishmania spp. infection among PWH and to define particular determinants that affect critically the epidemiological characteristics of VL-HIV coinfection and, potentially, its burden on public health. Two independent reviewers conducted a systematic literature search until June 30, 2022. Meta-analyses were conducted using random-effects models to calculate the summary prevalence and respective 95% confidence intervals (CI) of leishmaniasis among PWH. Meta-regression analysis was performed to investigate the impact of putative effect modifiers, such as the mean CD4 cell count, on the major findings. Thirty-four studies were eligible, yielding a summary prevalence of 6% (95%CI, 4-11%) for leishmaniasis (n = 1583) among PWH (n = 85,076). Higher prevalence rates were noted in Asia (17%, 95%CI, 9-30%) and America (9%, 95%CI, 5-17%) than in Europe (4%, 95%CI, 2-8%). Prevalence rates were significantly mediated by the age, sex, and CD4 cell count of participants. Heterogeneity remained significant in all meta-analyses (p < 0.0001). In the majority of included studies, people were coinfected with HIV and Leishmania species associated with VL, as opposed to those associated with cutaneous leishmaniasis. No sign of publication bias was shown (p = 0.06). Our summary of published studies on leishmaniasis among PWH is important to provide prevalence estimates and define potential underlying factors that could guide researchers to generate and further explore specific etiologic hypotheses.

Indexed as

CoinfectionHIV InfectionsLeishmaniasisLeishmaniasis, VisceralHIVHumansPrevalenceCoinfectionHIVLeishmaniaMeta-analysisPrevalenceSystematic review

Identifiers

PMID36427170
PMCPMC9816214
OpenAlexW4309951158

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.